Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities investigation

Pomerantz Investigates Ultragenyx After Failed Angelman Trial

Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 23, 2026

Sentiment
-20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The failed Phase 3 trial and subsequent 44% stock drop have severely damaged investor confidence in Ultragenyx, and the securities investigation adds legal and reputational risk that could further pressure the stock. The event highlights the high-risk nature of clinical-stage biotech investments, potentially affecting sentiment across the sector.

pharmaceuticals biotechnology legal services

Pomerantz LLP announced it is investigating claims on behalf of investors of Ultragenyx regarding potential securities fraud or other unlawful business practices. The investigation follows Ultragenyx's September 2, 2026 press release announcing results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome. According to the press release, the study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score nor the key secondary endpoint of net response in Multidomain Responder Index (MDRI). On this news, Ultragenyx's stock price fell $11.68 per share, or 44.03%, to close at $14.85 per share on September 3, 2026. Pomerantz LLP, a law firm specializing in corporate, securities, and antitrust class litigation, is advising affected investors to contact Danielle Peyton to join the potential class action. The investigation concerns whether Ultragenyx and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices.

90 Ultragenyx reported failed Phase 3 study
85 Ultragenyx stock fell 44 percent
70 Pomerantz LLP investigating securities fraud claims Ultragenyx
stock
Ultragenyx is the target of the securities investigation following its failed Phase 3 Aspire study for apazunersen in Angelman syndrome, which caused its stock to plummet 44%. The company faces potential legal liability and reputational damage, with its market value and investor trust significantly impaired.
Importance 100.0 Sentiment -70.0
priv
Pomerantz LLP is the law firm investigating potential securities fraud claims against Ultragenyx on behalf of investors. The investigation could lead to a class action lawsuit, enhancing the firm's profile in securities litigation but posing legal risks for Ultragenyx.
Importance 60.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.